Back to Search Start Over

Real‐world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1‐ and 2‐infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group

Authors :
Takashi Sato
Hiroyuki Kimura
Chikara Ogawa
Hirotaka Arai
Nami Mori
Masayuki Kurosaki
Atsunori Kusakabe
Takehiro Akahane
Kouji Joko
Masahiko Kondo
Chitomi Hasebe
Yasushi Ide
Shinichiro Nakamura
Koichiro Furuta
Toshifumi Tada
Akeri Mitsuda
Namiki Izumi
Hitoshi Yagisawa
Yasushi Uchida
Hiroyuki Marusawa
Haruhiko Kobashi
Yuji Kojima
Ryoichi Narita
Keiji Tsuji
Source :
Journal of Medical Virology. 93:6247-6256
Publication Year :
2021
Publisher :
Wiley, 2021.

Abstract

The real-world virological efficacy and safety of interferon-free direct-acting antiviral (DAA) therapy with sofosbuvir (SOF) and velpatasvir (VEL) were assessed in hepatitis C virus (HCV) genotype 1- and 2-infected patients with decompensated cirrhosis. A total of 65 patients with HCV-related decompensated cirrhosis (Child-Pugh score of 7 points or more) who were treated with the SOF/VEL regimen were enrolled. The sustained virological response (SVR) rate and safety profile were analyzed. SVR was defined as undetectable serum HCV RNA at 12 weeks after the end of treatment (SVR12). The percentages of patients with undetectable HCV RNA at 4, 8, and 12 weeks after the start of therapy were 81.2% (95% confidence interval [CI], 69.5-89.9) (52/64), 98.4% (95% CI, 91.2-100.0) (60/61), and 98.5% (95% CI, 91.7-100.0) (64/65), respectively. The overall SVR rate was 92.3% (95% CI, 83.0-97.5) (60/65). Albumin-bilirubin (ALBI) scores decreased during and after treatment (p

Details

ISSN :
10969071 and 01466615
Volume :
93
Database :
OpenAIRE
Journal :
Journal of Medical Virology
Accession number :
edsair.doi.dedup.....f2a82460d15c40a60aa82a873555a688
Full Text :
https://doi.org/10.1002/jmv.27157